Immunosenescence And Cancer Predisposition In Pediatric Transplant Recipients: An Emerging Paradigm
Even though they are young, children who undergo organ or stem cell transplantation often experience a rapid aging of their immune system, a process known as immunosenescence. This premature aging is largely triggered by factors such as certain medications used during transplantation (like anti-thymocyte globulin), reactivation of common viruses like cytomegalovirus, problems with the thymus (an organ crucial for immune cell development), and the long-term use of drugs to suppress the immune system.
This accelerated immune decline has serious consequences, making these young patients much more susceptible to developing various cancers, with some studies showing a 4- to 20-fold increase in cancer incidence compared to the general population. Their immune cells, particularly T cells, start to show characteristics typically seen in much older individuals, such as reduced ability to fight off threats and shortened protective caps on their DNA called telomeres.
Recognizing this challenge, a new approach is emerging that views pediatric transplantation through the lens of aging. This involves using advanced tools, such as specialized blood tests that look at immune cell markers, measure telomere length, and assess “epigenetic clocks” (biological markers of aging), to better understand each child’s individual risk. The goal is to develop personalized strategies, including carefully adjusting immunosuppressive medications, closely managing viral infections, and exploring new treatments that can target aging cells, help regenerate the thymus, or influence metabolic pathways. By doing so, medical professionals aim to strike a delicate balance: ensuring the transplanted organ survives, preserving the child’s immune health, and actively working to prevent cancer in this vulnerable population.
Source: link to paper